Amy Marren

Amy Marren is a Senior Director and Evidence Dissemination Lead in Inflammation and Immunology at Pfizer, a role they have held since 2019. Previously, Marren served as Director of Inflammation in the Specialty Care Business Unit and Medical Director for Xeljanz Gastroenterology, where they contributed to medical strategies and the global launch of Xeljanz for ulcerative colitis. Marren's extensive experience includes a position as Director of Global Medical Affairs, supporting FDA approvals and leading clinical strategies for oral contraceptives. They hold an MD from Temple University School of Medicine and a B.A. and M.A. in Biology from Gettysburg College and Temple University, respectively.